东阳光药与深圳晶泰订立战略合作协议，拟成立合资公司，共建AI驱动药物研发平台

Core Viewpoint - Dongyangguang Pharmaceutical (600673) has entered into a strategic cooperation agreement with Shenzhen Jingtai Technology Co., Ltd. to establish a joint venture focused on AI-driven drug research and development [1] Group 1: Joint Laboratory and Drug Development - The companies will establish a joint laboratory aimed at developing innovative drug pipelines, focusing on autoimmune diseases, utilizing AI-driven automation to create a closed-loop R&D process [1] - The collaboration will leverage Shenzhen Jingtai's automated experimental platform technology and deployment experience to discover candidate drugs [1] Group 2: Development and Promotion of Large Models - The partnership will combine Dongyangguang's multi-target high-quality non-clinical data with Shenzhen Jingtai's AI algorithm platform to develop a PB-PK predictive model that aligns with industry-leading commercial software [2] - An AI drug development engine covering the entire drug development lifecycle will be co-built [2] Group 3: Business Model Creation - The companies plan to create a "Model as a Service" (MaaS) business model by establishing an AI supercomputing platform that supports computation, data development, and ecosystem sharing [3] - The collaboration aims to convert data assets and AI products into a MaaS model, opening the results to academia and industry [3] - The board believes that the strategic cooperation agreement provides valuable opportunities for both parties to utilize their resources and expertise for mutual benefit and synergy [3]